Novo Nordisk partners on stem cell-based therapies – The Pharma Letter
The Pharma LetterNovo Nordisk partners on stem cell-based therapiesThe Pharma LetterDanish diabetes care giant Novo Nordisk (NOV: N) today announced an increased commitment to stem cell-based therapies and an expansion of the focus on type 1 diabetes i… Continue reading
